Company Profile

Effective 1 November 2022, Diurnal Limited has been acquired by Neurocrine Biosciences, Inc.

Founded in 2004, DIURNAL®, a NEUROCRINE BIOSCIENCES® Company, is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions. We are committed to addressing major unmet clinical and patient needs in hormone replacement, initially by developing and marketing products for the rare and orphan diseases Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI).

Diurnal Limited (Company Number: 05237326) is registered in England & Wales. Registered office: Cardiff Medicentre, Heath Park, Cardiff CF14 4UJ, UK.